Does the media refer more to IONS or UTHR?

In the previous week, Ionis Pharmaceuticals had 18 more articles in the media than United Therapeutics. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 34 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.76 beat Ionis Pharmaceuticals' score of -0.01 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 5 Positive mention(s) 21 Neutral mention(s) 12 Negative mention(s) 2 Very Negative mention(s) Neutral United Therapeutics 14 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to IONS or INCY?

In the previous week, Ionis Pharmaceuticals had 35 more articles in the media than Incyte. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 17 mentions for Incyte. Incyte's average media sentiment score of 0.50 beat Ionis Pharmaceuticals' score of -0.01 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 5 Positive mention(s) 21 Neutral mention(s) 12 Negative mention(s) 2 Very Negative mention(s) Neutral Incyte 7 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Positive

Does the media refer more to INSM or IONS?

In the previous week, Ionis Pharmaceuticals had 43 more articles in the media than Insmed. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 9 mentions for Insmed. Insmed's average media sentiment score of 1.45 beat Ionis Pharmaceuticals' score of -0.01 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 7 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ionis Pharmaceuticals 4 Very Positive mention(s) 5 Positive mention(s) 21 Neutral mention(s) 12 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media prefer BNTX or IONS?

In the previous week, Ionis Pharmaceuticals had 38 more articles in the media than BioNTech. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 14 mentions for BioNTech. BioNTech's average media sentiment score of 0.36 beat Ionis Pharmaceuticals' score of -0.01 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Ionis Pharmaceuticals 4 Very Positive mention(s) 5 Positive mention(s) 21 Neutral mention(s) 12 Negative mention(s) 2 Very Negative mention(s) Neutral

Does the media favor IONS or ALNY?

In the previous week, Ionis Pharmaceuticals had 33 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 19 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.39 beat Ionis Pharmaceuticals' score of -0.01 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ionis Pharmaceuticals 4 Very Positive mention(s) 5 Positive mention(s) 21 Neutral mention(s) 12 Negative mention(s) 2 Very Negative mention(s) Neutral Alnylam Pharmaceuticals 4 Very Positive mention(s) 3 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral

Ionis Pharmaceuticals (IONS) Competitors

$27.86 +0.55 (+2.02%)

As of 11:11 AM Eastern

Compare

IONS vs. UTHR, INCY, INSM, BNTX, and ALNY

Should you buy Ionis Pharmaceuticals stock or one of its competitors? Ionis Pharmaceuticals's main competitors and comparable companies include United Therapeutics (UTHR), Incyte (INCY), Insmed (INSM), BioNTech (BNTX), and Alnylam Pharmaceuticals (ALNY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Ionis Pharmaceuticals compare to United Therapeutics?

Ionis Pharmaceuticals (NASDAQ:IONS) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, dividends, profitability, earnings, risk, analyst recommendations, media sentiment and institutional ownership.

United Therapeutics has a net margin of 38.61% compared to Ionis Pharmaceuticals' net margin of -56.98%. United Therapeutics' return on equity of 19.18% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-56.98%	-120.62%	-16.99%
United Therapeutics	38.61%	19.18%	17.07%

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 94.1% of United Therapeutics shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by insiders. Comparatively, 8.6% of United Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

United Therapeutics has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	4.82	-$381.39M	-$3.32	N/A
United Therapeutics	$3.18B	7.94	$1.33B	$26.50	22.39

In the previous week, Ionis Pharmaceuticals had 18 more articles in the media than United Therapeutics. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 34 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 0.76 beat Ionis Pharmaceuticals' score of -0.01 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	5 Positive mention(s)	21 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Neutral
United Therapeutics	14 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ionis Pharmaceuticals currently has a consensus target price of $78.00, suggesting a potential upside of 185.61%. United Therapeutics has a consensus target price of $676.40, suggesting a potential upside of 14.00%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Ionis Pharmaceuticals is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.78
United Therapeutics	1 Sell rating(s)	3 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.69

Ionis Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, meaning that its share price is 51% less volatile than the broader market.

Summary

United Therapeutics beats Ionis Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Incyte?

Ionis Pharmaceuticals (NASDAQ:IONS) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, valuation, media sentiment, risk, earnings, analyst recommendations, dividends and institutional ownership.

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. Comparatively, 97.0% of Incyte shares are held by institutional investors. 1.8% of Ionis Pharmaceuticals shares are held by company insiders. Comparatively, 16.2% of Incyte shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 35 more articles in the media than Incyte. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 17 mentions for Incyte. Incyte's average media sentiment score of 0.50 beat Ionis Pharmaceuticals' score of -0.01 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	5 Positive mention(s)	21 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Neutral
Incyte	7 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Positive

Incyte has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	4.82	-$381.39M	-$3.32	N/A
Incyte	$5.14B	4.82	$1.29B	$1.88	64.73

Ionis Pharmaceuticals presently has a consensus price target of $78.00, indicating a potential upside of 185.61%. Incyte has a consensus price target of $132.86, indicating a potential upside of 9.17%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Ionis Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.78
Incyte	1 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.40

Ionis Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Incyte has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market.

Incyte has a net margin of 6.71% compared to Ionis Pharmaceuticals' net margin of -56.98%. Incyte's return on equity of 7.92% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-56.98%	-120.62%	-16.99%
Incyte	6.71%	7.92%	6.12%

Summary

Incyte beats Ionis Pharmaceuticals on 12 of the 16 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Insmed has a net margin of -39.85% compared to Ionis Pharmaceuticals' net margin of -56.98%. Insmed's return on equity of -96.38% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-39.85%	-96.38%	-32.55%
Ionis Pharmaceuticals	-56.98%	-120.62%	-16.99%

Ionis Pharmaceuticals has higher revenue and earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.71	-$1.28B	-$2.82	N/A
Ionis Pharmaceuticals	$944M	4.82	-$381.39M	-$3.32	N/A

Insmed has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, indicating that its share price is 57% less volatile than the broader market.

Insmed presently has a consensus target price of $196.52, indicating a potential upside of 66.45%. Ionis Pharmaceuticals has a consensus target price of $78.00, indicating a potential upside of 185.61%. Given Ionis Pharmaceuticals' higher probable upside, analysts clearly believe Ionis Pharmaceuticals is more favorable than Insmed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	1 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.92
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.78

93.9% of Ionis Pharmaceuticals shares are held by institutional investors. 2.1% of Insmed shares are held by insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Ionis Pharmaceuticals had 43 more articles in the media than Insmed. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 9 mentions for Insmed. Insmed's average media sentiment score of 1.45 beat Ionis Pharmaceuticals' score of -0.01 indicating that Insmed is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	7 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Ionis Pharmaceuticals	4 Very Positive mention(s)	5 Positive mention(s)	21 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Insmed beats Ionis Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Ionis Pharmaceuticals (NASDAQ:IONS) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

In the previous week, Ionis Pharmaceuticals had 38 more articles in the media than BioNTech. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 14 mentions for BioNTech. BioNTech's average media sentiment score of 0.36 beat Ionis Pharmaceuticals' score of -0.01 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Ionis Pharmaceuticals	4 Very Positive mention(s)	5 Positive mention(s)	21 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Neutral

BioNTech presently has a consensus target price of $122.27, indicating a potential upside of 43.78%. Ionis Pharmaceuticals has a consensus target price of $78.00, indicating a potential upside of 185.61%. Given Ionis Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ionis Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.78

BioNTech has a beta of 1.28, meaning that its share price is 28% more volatile than the broader market. Comparatively, Ionis Pharmaceuticals has a beta of 0.43, meaning that its share price is 57% less volatile than the broader market.

Ionis Pharmaceuticals has a net margin of -56.98% compared to BioNTech's net margin of -61.39%. BioNTech's return on equity of -4.51% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-61.39%	-4.51%	-3.96%
Ionis Pharmaceuticals	-56.98%	-120.62%	-16.99%

Ionis Pharmaceuticals has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	6.62	-$1.29B	-$6.85	N/A
Ionis Pharmaceuticals	$944M	4.82	-$381.39M	-$3.32	N/A

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 1.8% of Ionis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats BioNTech on 9 of the 17 factors compared between the two stocks.

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Ionis Pharmaceuticals (NASDAQ:IONS) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, media sentiment, dividends, profitability, analyst recommendations, valuation, institutional ownership and earnings.

Alnylam Pharmaceuticals has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ionis Pharmaceuticals	$944M	4.82	-$381.39M	-$3.32	N/A
Alnylam Pharmaceuticals	$5.01B	4.19	$313.75M	$19.26	8.13

93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. 1.8% of Ionis Pharmaceuticals shares are owned by insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Alnylam Pharmaceuticals has a net margin of 52.85% compared to Ionis Pharmaceuticals' net margin of -56.98%. Alnylam Pharmaceuticals' return on equity of 155.33% beat Ionis Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ionis Pharmaceuticals	-56.98%	-120.62%	-16.99%
Alnylam Pharmaceuticals	52.85%	155.33%	44.81%

Ionis Pharmaceuticals presently has a consensus price target of $78.00, indicating a potential upside of 185.61%. Alnylam Pharmaceuticals has a consensus price target of $305.86, indicating a potential upside of 95.25%. Given Ionis Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Ionis Pharmaceuticals is more favorable than Alnylam Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ionis Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	19 Buy rating(s)	0 Strong Buy rating(s)	2.78
Alnylam Pharmaceuticals	0 Sell rating(s)	10 Hold rating(s)	15 Buy rating(s)	1 Strong Buy rating(s)	2.65

Ionis Pharmaceuticals has a beta of 0.43, meaning that its stock price is 57% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market.

In the previous week, Ionis Pharmaceuticals had 33 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 52 mentions for Ionis Pharmaceuticals and 19 mentions for Alnylam Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.39 beat Ionis Pharmaceuticals' score of -0.01 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ionis Pharmaceuticals	4 Very Positive mention(s)	5 Positive mention(s)	21 Neutral mention(s)	12 Negative mention(s)	2 Very Negative mention(s)	Neutral
Alnylam Pharmaceuticals	4 Very Positive mention(s)	3 Positive mention(s)	9 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IONS vs. The Competition

Export

Metric	Ionis Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.62B	$4.08B	$7.85B	$12.00B
Dividend Yield	N/A	3.62%	2.46%	4.50%
P/E Ratio	-8.36	24.51	34.43	30.31
Price / Sales	4.92	16.78	8.84	5.84
Price / Cash	N/A	26.89	22.23	22.80
Price / Book	11.81	4.11	4.38	3.77
Net Income	-$381.39M	-$22.78M	$3.51B	$390.69M
7 Day Performance	-29.32%	-3.18%	-1.80%	-0.60%
1 Month Performance	-34.25%	-6.16%	-4.19%	-6.88%
1 Year Performance	-60.10%	-0.85%	0.57%	-6.20%

Ionis Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IONS Ionis Pharmaceuticals	2.9932 of 5 stars	$27.86 +2.0%	$78.00 +179.9%	-62.4%	$4.62B	$944M	N/A	1,402	Trending News Earnings Report Analyst Forecast
UTHR United Therapeutics	4.6178 of 5 stars	$582.46 +3.6%	$676.40 +16.1%	+28.6%	$26.10B	$3.18B	21.98	1,400	Insider Trade Analyst Revision
INCY Incyte	2.8744 of 5 stars	$121.89 +1.9%	$132.86 +9.0%	+12.4%	$25.04B	$5.14B	57.95	2,844	Insider Trade
INSM Insmed	3.4205 of 5 stars	$116.10 +1.5%	$196.52 +69.3%	-39.3%	$24.13B	$606.42M	N/A	1,664	Positive News
BNTX BioNTech	3.8871 of 5 stars	$87.51 flat	$122.27 +39.7%	-23.8%	$22.94B	$3.25B	N/A	7,807

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IONS) was last updated on 11/13/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. UTHR, INCY, INSM, BNTX, and ALNY

How does Ionis Pharmaceuticals compare to United Therapeutics?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Summary

How does Ionis Pharmaceuticals compare to BioNTech?

Summary

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ionis Pharmaceuticals (IONS) Competitors

IONS vs. UTHR, INCY, INSM, BNTX, and ALNY

How does Ionis Pharmaceuticals compare to United Therapeutics?

Is IONS or UTHR more profitable?

Do institutionals and insiders hold more shares of IONS or UTHR?

Which has preferable valuation and earnings, IONS or UTHR?

Does the media refer more to IONS or UTHR?

Do analysts recommend IONS or UTHR?

Which has more volatility & risk, IONS or UTHR?

Summary

How does Ionis Pharmaceuticals compare to Incyte?

Do institutionals & insiders hold more shares of IONS or INCY?

Does the media refer more to IONS or INCY?

Which has stronger earnings & valuation, IONS or INCY?

Do analysts recommend IONS or INCY?

Which has more volatility and risk, IONS or INCY?

Is IONS or INCY more profitable?

Summary

How does Ionis Pharmaceuticals compare to Insmed?

Is INSM or IONS more profitable?

Which has higher earnings and valuation, INSM or IONS?

Which has more volatility & risk, INSM or IONS?

Do analysts prefer INSM or IONS?

Do insiders and institutionals hold more shares of INSM or IONS?

Does the media refer more to INSM or IONS?

Summary

How does Ionis Pharmaceuticals compare to BioNTech?

Does the media prefer BNTX or IONS?

Do analysts rate BNTX or IONS?

Which has more volatility & risk, BNTX or IONS?

Is BNTX or IONS more profitable?

Which has stronger valuation & earnings, BNTX or IONS?

Do institutionals & insiders believe in BNTX or IONS?

Summary

How does Ionis Pharmaceuticals compare to Alnylam Pharmaceuticals?

Which has preferable earnings & valuation, IONS or ALNY?

Do insiders and institutionals believe in IONS or ALNY?

Is IONS or ALNY more profitable?

Do analysts recommend IONS or ALNY?

Which has more volatility and risk, IONS or ALNY?

Does the media favor IONS or ALNY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IONS vs. The Competition

Ionis Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools